| Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 |
SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia. The Tour brings rugby fans' dreams to life over a six-week period. |
globenewswire.com |
2025-05-15 13:00:00 |
Czytaj oryginał (ang.) |
| Top 15 High-Growth Dividend Stocks To Consider For May 2025 |
My Top 15 High-Growth Dividend stocks for April 2025 outperformed SPY and VIG, posting a 0.12% gain versus SPY's -0.87% and VIG's -1.53%. Year-to-date, the Top 15 list returned -0.36%, outperforming VIG's -2.46% and SPY's -5.40%, aiming for a long-term 12% return. The May 2025 Top 15 stocks offer a 1.33% average dividend yield with a 21.25% 5-year dividend growth rate and are 29% undervalued. |
seekingalpha.com |
2025-05-02 15:21:26 |
Czytaj oryginał (ang.) |
| Why ResMed (RMD) is a Top Growth Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-05-01 14:46:10 |
Czytaj oryginał (ang.) |
| Resmed Acquires VirtuOx |
Acquisition supports Resmed's growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers Acquisition supports Resmed's growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers |
globenewswire.com |
2025-05-01 13:00:00 |
Czytaj oryginał (ang.) |
| ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy? |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-04-25 14:55:47 |
Czytaj oryginał (ang.) |
| Buy These 5 Low-Leverage Stocks to Counter Market Volatility |
The crux of safe investment lies in choosing a company that is not burdened with debt. You can buy BILI, KINS, ENGIY, ASML and RMD. |
zacks.com |
2025-04-25 12:10:39 |
Czytaj oryginał (ang.) |
| ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast |
On Wednesday, ResMed Inc RMD reported that third-quarter adjusted EPS was $2.37, beating the consensus of $2.36. |
benzinga.com |
2025-04-24 19:24:01 |
Czytaj oryginał (ang.) |
| ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market |
RMD's stellar third-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business. |
zacks.com |
2025-04-24 12:25:37 |
Czytaj oryginał (ang.) |
| ResMed: Cornering The Market In Sleep Solutions |
ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, enhancing its product portfolio, customer experience, and expanding into new markets, justifying its premium share price. Concerns about GLP-1 drugs reducing ResMed's market are countered by data suggesting increased overall health engagement, boosting interest in sleep health solutions. |
seekingalpha.com |
2025-04-24 09:12:03 |
Czytaj oryginał (ang.) |
| ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript |
ResMed Inc. (NYSE:RMD ) Q3 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Mick Farrell - Chairman & Chief Executive Officer Salli Schwartz - Chief Investor Relations Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Lyanne Harrison - Bank of America Margaret Kaczor - William Blair Davin Thillainathan - Goldman Sachs Anthony Petrone - Mizuho Group David Low - JPMorgan Saul Hadassin - Barrenjoey Dan Hurren - MST Matt Taylor - Jefferies Steve Wheen - Jarden David Bailey - Morgan Stanley Brett Fishbin - KeyBanc Capital Markets Operator Greetings, and welcome to the Q3 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. |
seekingalpha.com |
2025-04-23 23:16:19 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About ResMed (RMD) Q3 Earnings |
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-04-23 23:00:42 |
Czytaj oryginał (ang.) |
| ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates |
ResMed (RMD) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.13 per share a year ago. |
zacks.com |
2025-04-23 22:20:40 |
Czytaj oryginał (ang.) |
| ResMed slightly beats quarterly profit estimates on sleep devices demand |
Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder. |
reuters.com |
2025-04-23 21:08:44 |
Czytaj oryginał (ang.) |
| Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 |
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com |
globenewswire.com |
2025-04-23 20:05:00 |
Czytaj oryginał (ang.) |
| Resmed Names Salli Schwartz as Chief Investor Relations Officer |
Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community |
globenewswire.com |
2025-04-21 21:00:00 |
Czytaj oryginał (ang.) |
| What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings |
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025. |
zacks.com |
2025-04-17 14:20:51 |
Czytaj oryginał (ang.) |
| ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth |
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-16 15:06:27 |
Czytaj oryginał (ang.) |
| Here's Why ResMed (RMD) is a Strong Growth Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-04-15 14:45:36 |
Czytaj oryginał (ang.) |
| Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength? |
ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-04-08 13:41:12 |
Czytaj oryginał (ang.) |
| RMD Stock Benefits From the Launch of NightOwl Across US |
Resmed launches NightOwl, an FDA-cleared home sleep apnea test, in the United States to diagnose OSA at home. |
zacks.com |
2025-04-04 13:10:39 |
Czytaj oryginał (ang.) |
| Here's Why ResMed (RMD) is a Strong Growth Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-26 12:45:24 |
Czytaj oryginał (ang.) |
| ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep |
New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships |
globenewswire.com |
2025-02-26 05:00:00 |
Czytaj oryginał (ang.) |
| 3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD) |
ResMed (RMD) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2025-02-20 15:45:19 |
Czytaj oryginał (ang.) |
| Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher |
ResMed (RMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
zacks.com |
2025-02-14 12:56:10 |
Czytaj oryginał (ang.) |
| Jan De Witte joins GHO Capital as Operating Partner |
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. |
globenewswire.com |
2025-02-11 06:30:00 |
Czytaj oryginał (ang.) |
| Why ResMed (RMD) is a Top Growth Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-10 12:47:19 |
Czytaj oryginał (ang.) |
| Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions |
ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Watch, underscores a significant growth opportunity, with millions still undiagnosed and untreated globally. Concerns over GLP-1 drugs reducing CPAP demand have diminished. |
seekingalpha.com |
2025-02-10 12:38:23 |
Czytaj oryginał (ang.) |
| Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks |
Three companies that are better positioned to withstand Trump's tariff challenges are ResMed, Hims & Hers Health and Medtronic. |
zacks.com |
2025-02-05 15:15:31 |
Czytaj oryginał (ang.) |
| Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes" |
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market. |
zacks.com |
2025-02-04 15:45:33 |
Czytaj oryginał (ang.) |
| Stock Of The Day: Trading The Range In ResMed |
ResMed Inc. RMD shares are consolidating on Monday. This follows Friday's decline of more than 8%. |
benzinga.com |
2025-02-03 14:59:07 |
Czytaj oryginał (ang.) |
| Here's Why ResMed (RMD) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-03 12:55:54 |
Czytaj oryginał (ang.) |
| ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run? |
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2025-01-31 12:16:13 |
Czytaj oryginał (ang.) |
| ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript |
ResMed Inc. (NYSE:RMD ) Q2 2025 Earnings Conference Call January 30, 2025 4:30 PM ET Company Participants Mike Ott - Senior Manager, IR Michael Farrell - Chairman and Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Dan Hurren - MST Davin Thillainathan - Goldman Sachs Lyanne Harrison - Bank of America Laura Sutcliffe - UBS Craig Wong-Pan - RBC Mike Matson - Needham & Company Anthony Petrone - Mizuho Group Mathieu Chevrier - Citi David Low - JPMorgan Brett Fishbin - KeyBanc Capital Markets Operator Welcome to the Q2 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Matt, and I'll be your operator for today's call. |
seekingalpha.com |
2025-01-30 23:10:41 |
Czytaj oryginał (ang.) |
| ResMed: Digital Health Drives Q2 Growth |
ResMed (RMD 1.89%), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst consensus forecasts with adjusted EPS of $2.43 topping the $2.32 estimate and revenue of $1.282 billion beating the expected $1.266 billion. |
fool.com |
2025-01-30 21:44:26 |
Czytaj oryginał (ang.) |
| Compared to Estimates, ResMed (RMD) Q2 Earnings: A Look at Key Metrics |
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-01-30 21:30:31 |
Czytaj oryginał (ang.) |
| ResMed (RMD) Tops Q2 Earnings and Revenue Estimates |
ResMed (RMD) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $1.88 per share a year ago. |
zacks.com |
2025-01-30 20:21:09 |
Czytaj oryginał (ang.) |
| ResMed beats quarterly profit estimates on demand for sleep disorder devices |
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. |
reuters.com |
2025-01-30 19:21:55 |
Czytaj oryginał (ang.) |
| ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025 |
Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com |
globenewswire.com |
2025-01-30 18:05:00 |
Czytaj oryginał (ang.) |
| ResMed (RMD) Earnings Expected to Grow: Should You Buy? |
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-01-23 13:06:45 |
Czytaj oryginał (ang.) |
| 5 Sectors and Stocks Set to Shine This Earnings Season |
We have highlighted stocks from the sectors that are expected to move higher this earnings season. |
zacks.com |
2025-01-14 14:56:11 |
Czytaj oryginał (ang.) |
| ResMed Gains 37.8% in a Year: What's Driving the Stock? |
RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is concerning. |
zacks.com |
2025-01-03 11:35:49 |
Czytaj oryginał (ang.) |
| 3 GARP Stocks That Investors Can Scoop Up for Maximum Returns |
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, RJF and KBR are some stocks that hold promise. |
zacks.com |
2025-01-03 11:35:38 |
Czytaj oryginał (ang.) |
| My Top 15 High Growth Dividend Stocks For January 2025 |
The SPDR S&P 500 ETF Trust ended 2024 on a sour note, losing 2.41% in December and finishing the year up 24.89%. The Top 15 dividend growth stocks for January 2025 offer an average dividend yield of 1.21% and appear to be about 27% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.33% compound annual growth rate. |
seekingalpha.com |
2025-01-03 00:49:14 |
Czytaj oryginał (ang.) |
| Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report? |
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2024-12-31 15:25:26 |
Czytaj oryginał (ang.) |
| Here's Why ResMed (RMD) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-30 12:46:47 |
Czytaj oryginał (ang.) |
| Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound |
Shares of ResMed (RMD) and Inspire Medical Systems (INSP) fell Monday as the companies behind products to treat sleep apnea faced a new threat from weight-loss drugs. |
investopedia.com |
2024-12-23 16:59:31 |
Czytaj oryginał (ang.) |
| 3 Reasons Growth Investors Will Love ResMed (RMD) |
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2024-12-23 15:46:06 |
Czytaj oryginał (ang.) |
| 2 Sleep Apnea Stocks in Focus Today |
Eli Lilly and Co (NYSE:LLY) is in focus today, after the U.S. Food & Drug Administration (FDA) approved its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity -- the first such treatment in the country. |
schaeffersresearch.com |
2024-12-23 12:51:58 |
Czytaj oryginał (ang.) |
| Why ResMed (RMD) is a Top Growth Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-23 12:46:11 |
Czytaj oryginał (ang.) |
| 4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2025 |
Investing in large-cap MedTech stocks like MCK, PEN, CAH and PEN can be profitable for investors in 2025. |
zacks.com |
2024-12-20 12:26:08 |
Czytaj oryginał (ang.) |
| Why ResMed (RMD) is a Top Value Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-13 12:41:08 |
Czytaj oryginał (ang.) |
| RMD or PODD: Which Is the Better Value Stock Right Now? |
Investors interested in Medical - Products stocks are likely familiar with ResMed (RMD) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-12-12 14:41:20 |
Czytaj oryginał (ang.) |
| 5 Solid Dividend Growth Stocks to Buy Now |
InterDigital, ResMed, Greenbrier Companies, Charles River Associates and Kontoor Brands seem excellent choices for your portfolio. |
zacks.com |
2024-12-12 12:15:40 |
Czytaj oryginał (ang.) |
| Scoop Up These 3 GARP Stocks to Receive Handsome Returns |
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. RMD, OUT and CTAS are some stocks that hold promise. |
zacks.com |
2024-12-09 11:10:36 |
Czytaj oryginał (ang.) |
| Here is Why Growth Investors Should Buy ResMed (RMD) Now |
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2024-12-09 08:47:18 |
Czytaj oryginał (ang.) |
| 4 Medical Product Stocks to Buy From a Prospective Industry |
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors. |
zacks.com |
2024-12-04 12:45:35 |
Czytaj oryginał (ang.) |
| Canada Sleep Apnea Devices Market Research Report 2024: Opportunities and Forecasts to 2029 Featuring Braebon Medical, VitalAire, FPM Solutions, SomnoMed, and ResMed |
Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Canada Sleep Apnea Devices Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's offering. Canada Sleep Apnea Devices Market was valued at USD 338.54 Million in 2023 and is expected to reach USD 465.53 Million by 2029 with a CAGR of 5.41% |
globenewswire.com |
2024-12-04 06:13:00 |
Czytaj oryginał (ang.) |
| Here's Why ResMed (RMD) is a Strong Momentum Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-03 12:55:53 |
Czytaj oryginał (ang.) |
| My Top 15 High-Growth Dividend Stocks For December 2024 |
The SPDR S&P 500 ETF Trust posted a strong gain of 5.96% in November, resuming its strong run in 2024. The Top 15 dividend growth stocks for December 2024 offer an average dividend yield of 1.2% and appear to be about 22% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 12.41% compound annual growth rate. |
seekingalpha.com |
2024-12-02 08:00:00 |
Czytaj oryginał (ang.) |
| RMD vs. LMAT: Which Stock Is the Better Value Option? |
Investors looking for stocks in the Medical - Products sector might want to consider either ResMed (RMD) or LeMaitre Vascular (LMAT). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-11-26 14:40:45 |
Czytaj oryginał (ang.) |